Breaking News

Tweet TWEET

Regulus to Present at Two Upcoming Investor Conferences

           Regulus to Present at Two Upcoming Investor Conferences

PR Newswire

LA JOLLA, Calif., Feb. 3, 2014

LA JOLLA, Calif., Feb. 3, 2014 /PRNewswire/ --Regulus Therapeutics Inc.
(NASDAQ:RGLS), a biopharmaceutical company leading the discovery and
development of innovative medicines targeting microRNAs, today announced that
Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a
company overview at the 16^th Annual BIO CEO & Investor Conference being held
at the Waldorf-Astoria Hotel in New York City on Tuesday, February 11, 2014 at
11:30 am EST. Dr. Xanthopoulos will also participate in a panel discussion at
the conference entitled "Delivering the RNA Goods" on Monday, February 10,
2014 at 10:30am EST.

Additionally, Neil Gibson, Ph.D., Chief Scientific Officer of Regulus, will
present a company overview at the Leerink Swann Global Healthcare Conference
being held at the Waldorf-Astoria Hotel in New York City on Thursday, February
13, 2014 at 8:05 am EST.

Each presentation will be webcast at the time of the presentation and can be
accessed on the Investor Relations page of the Company's website at
www.regulusrx.com. A replay of each webcast will be archived on the Company's
website following the presentation date.

About Regulus

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading
the discovery and development of innovative medicines targeting
microRNAs.Regulus is uniquely positioned to leverage a mature therapeutic
platform that harnesses the oligonucleotide drug discovery and development
expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc.,
which founded the company. Regulus has a well-balanced microRNA therapeutic
pipeline entering clinical development, an emerging microRNA biomarkers
platform to support its therapeutic programs, and a rich intellectual property
estate to retain its leadership in the microRNA field. Regulus intends to
focus its proprietary efforts on developing microRNA therapeutics for oncology
indications and orphan diseases and is currently advancing several programs
toward clinical development in oncology, fibrosis and metabolic diseases.
Regulus is also developing RG-101, a GalNAc-conjugated anti-miR targeting
microRNA-122, for the treatment of chronic hepatitis C virus infection.
Regulus' commitment to innovation and its leadership in the microRNA field
have enabled the formation of strategic alliances with AstraZeneca,
GlaxoSmithKline and Sanofi. In addition, the Company has established Regulus
microMarkers™, a research and development division focused on identifying
microRNAs as biomarkers of human disease, which is designed to support its
therapeutic pipeline, collaborators and strategic partners.

For more information, please visithttp://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements
associated with Regulus' expectations regarding future therapeutic and
commercial potential of Regulus' business plans, technologies and intellectual
property related to microRNA therapeutics being discovered and developed by
Regulus. Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or implied by such
forward-looking statements. Words such as "believes," "anticipates," "plans,"
"expects," "intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be incorrect. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of various risks
and uncertainties, which include, without limitation, risks associated with
the process of discovering, developing and commercializing drugs that are safe
and effective for use as human therapeutics, and in the endeavor of building a
business around such drugs. These and other risks concerning Regulus'
programs are described in additional detail in Regulus' SEC filings. All
forward-looking statements contained in this press release speak only as of
the date on which they were made. Regulus undertakes no obligation to update
such statements to reflect events that occur or circumstances that exist after
the date on which they were made.



SOURCE Regulus

Website: http://www.regulusrx.com
Contact: Amy Conrad, Director, Investor Relations and Corporate
Communications, aconrad@regulusrx.com, 858-202-6321, Media: Liz Bryan,
Spectrum Science, lbryan@spectrumscience.com, 202-955-6222 x2526
 
Press spacebar to pause and continue. Press esc to stop.